← Arcturus Therapeutics Holdings Inc. (ARCT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Arcturus Therapeutics Holdings Inc. (ARCT)
Pharmaceutical Preparations · market cap $388M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
7
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Arcturus Therapeutics (ARCT) is a ~$204M market-cap RNA medicines company with 124 employees, a pipeline spanning COVID-19 vaccines, OTC deficiency, and cystic fibrosis, and a lead Phase 3 asset in ARCT-2303 for COVID-19. The company holds $211.4M in cash against a market cap that is below net cash, implying the market assigns negative value to its operating pipeline. Revenue has declined sharply from $206M in 2022 to $82M in 2025 as COVID-related collaboration income has waned.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-06-15 (est.)Phase 2 · ARCT-032imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ARCT-810 | Phase 2 | OTC Deficiency |
| ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine | Phase 3 | COVID-19 Vaccines |
| ARCT-032 | Phase 2 | Cystic Fibrosis |
| ARCT-2304 | Phase 2 | Influenza, Human |
| ARCT-2303 | Phase 3 | COVID-19 |
| ARCT-165 | Phase 2 | COVID-19 |
| ARCT-021 Dose 1 | Phase 2 | SARS-CoV-2 |
Price & technical context
3-month
+81.5%
6-month
+68.3%
12-month
-28.3%
52-wk range
$5.53–$23.16
vs 50-day MA
+13.5%
vs 200-day MA
+56.0%
Realized vol
101.0%
Max drawdown
-78.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARCT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.